Antivascular endothelial growth factors for inflammatory chorioretinal disorders

Developments in Ophthalmology

Volumn 46, Issue , 2010, Pages 84-95

  Battaglia Parodi, Maurizio ^a   Iacono, Pierluigi ^b   Verbraak, Frank D ^c   Bandello, Francesco ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b IRCCS FONDAZIONE BIETTI   (Italy)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN A;

ARTICLE; BEHCET DISEASE; CHORIORETINITIS; DRUG ANTAGONISM; EYE DISEASE; HISTOPLASMOSIS; HUMAN; RETINA MACULA EDEMA; SUBRETINAL NEOVASCULARIZATION; SYNDROME; UVEITIS;

BEHCET SYNDROME; CHORIORETINITIS; CHOROIDAL NEOVASCULARIZATION; EYE DISEASES; HISTOPLASMOSIS; HUMANS; MACULAR EDEMA; SYNDROME; UVEITIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77956357104     PISSN: 02503751     EISSN: 16622790     Source Type: Book Series    
DOI: 10.1159/000320011     Document Type: Article

References (85)

1. Nozik RA, Dorsch W: A new chorioretinopathy associated with anterior uveitis. Am J Ophthalmol 1973;76:758-762.
2. Tatar O, Yoeruek E, Szurman P, et al: Effect of bevacizumab on inflammation and proliferation in human choroidal neovascularization. Arch Ophthalmol 2008;126:782-790.
3. Dryer RF, Gass J D M: Multifocal choroiditis and panuveitis. A syndrome that mimics ocular histoplasmosis. Arch Ophthalmol 1984;102:1776-1784.
4. Deutsch TA, Tessler HH: Inflammatory pseudohistoplasmosis. Ann Ophthalmol 1985;17:451-465.
5. Cantrill HL, Folk JC: Multifocal choroiditis associated with progressive subretinal fibrosis. Am J Ophthalmol 1986;101:170-180.
6. Morgan CM, Schatz H: Recurrent multifocal choroiditis. Ophthalmology 1986;93:1138-1147.
7. Lardenoye C W, Van der Lelij A, de Loos WS, et al: Peripheral multifocal chorioretinitis: a distinct clinical entity? Ophthalmology 1997;104:1820-1826.
8. Jampol LM, Wiredu A: MEWDS, MFC, PIC, AMN, AIBSE, and AZOOR: one disease or many? Retina 1995;15:373-378.
9. Brown J, Folk JC, Reddy CV, Kimura AE: Visual prognosis of multifocal choroiditis, punctate inner choroidopathy, and the diffuse subretinal fibrosis syndrome. Ophthalmology 1996;103:1100-1105.
10. Slakter JS, Giovannini A, Yannuzzi LA, et al: Indocyanine green angiography of multifocal choroiditis. Ophthalmology 1997;104:1813-1819.
11. Michel SS, Ekong A, Baltatzis S, Foster S: Multifocal choroiditis and panuveitis: immunomodulatory therapy. Ophthalmology 2002;109:378-383.
12. Flaxel CJ, Owens SL, Mulholland B, et al: The use of corticosteroids for choroidal neovascularisation in young patients. Eye 1998;12:266-272.
13. Nussenblatt RB, Coleman H, Jirawuthiworavong G, et al: The treatment of multifocal choroiditis associated choroidal neovascularization with sirolimus (rapamycin). Acta Ophthalmol Scand 2007;85:230-231.
14. Michel SS, Ekong A, Baltatzis S, Foster CS: Multifocal choroiditis and panuveitis: immunomodulatory therapy. Ophthalmology 2002;109:378-383.
15. Olsen T W, Capone A, Sternberg P, et al: Subfoveal choroidal neovascularization in punctate inner choroidopathy. Surgical management and pathologic findings. Ophthalmology 1996;103:2061-2069.
16. Thomas MA, Dickinson JD, Melberg NS, et al: Visual results after surgical removal of subfoveal choroidal neovascular membranes. Ophthalmology 1994;101:1384-1396.
17. Spaide R F, Freund KB, Slakter J, et al: Treatment of subfoveal choroidal neovascularization associated with multifocal choroiditis and panuveitis with photodynamic therapy. Retina 2002;22:545-549.
18. Parodi MB, Di Crecchio L, Lanzetta P, et al: Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization associated with multifocal choroiditis. Am J Ophthalmol 2004;138:263-269.
19. Parodi MB, Iacono P, Spasse S, Ravalico G: Photodynamic therapy for juxtafoveal choroidal neovascularization associated with multifocal choroiditis. Am J Ophthalmol 2006;141:23-26.
20. Chan WM, Lai T Y, Liu DT, Lam DS: Intravitreal bevacizumab (Avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin. Am J Ophthalmol 2007;143:977-983.
21. Chang LK, Spaide RF, Brue C, et al: Bevacizumab treatment for subfoveal choroidal neovascularization from causes other than age-related macular degeneration. Arch Ophthalmol 2008;126:941-945.
22. Fine HF, Zhitomirsky IB, Freund KB, et al: Bevacizumab (Avastin) and ranibizumab (Lucentis) for choroidal neovascularization in multifocal choroiditis. Retina 2009;29:8-12.
23. Shimada H, Yuzawa M, Hirose T, et al: Pathological findings of multifocal choroiditis with panuveitis and punctate inner choroidopathy. Jpn J Ophthalmol 2008;52:282-288.
24. Reche-Frutos J, Calvo-Gonzalez C, Donate-Lopez J, Garcia-Feijoo J: Early neovascular bridging of choroidal neovascularization after ranibizumab treatment. Graefes Arch Clin Exp Ophthalmol 2009;247:1427-1430.
25. Prasad AG, Van Gelder RN: Presumed ocular histoplasmosis syndrome. Curr Opin Ophthalmol 2005;16:364-368.
26. Brown DM, Weingeist TA, Smith RE: Histoplasmosis; in Pepose JS, Holland GN, Wilhelmus KR (eds): Ocular Infection and Immunity. St Louis, Mosby, 1996, pp 1252-1261.
27. Kleiner RC, Ratner CM, Enger C, Fine SL: Subfoveal neovascularization in the ocular histoplasmosis syndrome: a natural history study. Retina 1988;8:225-229.
28. Ciulla TA, Piper HC, Xiao M, Wheat LJ: Presumed ocular histoplasmosis syndrome: update on epidemiology, pathogenesis, and photodynamic, antiangiogenic, and surgical therapies. Curr Opin Opthalmol 2001;12:442-449.
29. Olk JR, Burgess DB, McCormick PA: Subfoveal and juxtafoveal subretinal neovascularization in the presumed ocular histoplasmosis syndrome: visual prognosis. Ophthalmology 1984;91:1592-1602.
30. Macular Photocoagulation Study Group: Krypton laser photocoagulation for neovascular lesions of ocular histoplasmosis: results of a randomized clinical trial. Arch Ophthalmol 1987;105:1499-1507.
31. Martidis A, Miller DG, Ciulla TA, Danis RP, Moorthy RS: Corticosteroids as an antiangiogenic agent for histoplasmosis-related subfoveal choroidal neovascularization. J Ocul Pharmacol Ther 1999;15:425-428.
32. Rechtman E, Allen VD, Danis R P, et al, Intravitreal triamcinolone for choroidal neovascularization in ocular histoplasmosis syndrome. Am J Ophthalmol 2003;136:739-741.
33. Breger AS, Conway M, del Priore LV, et al: Submacular surgery for subfoveal choroidal neovascular membranes in patients with presumed ocular histoplasmosis. Arch Ophthalmol 1997;115:991-996.
34. Submacular Surgery Trials Research Group: Surgical removal vs. observation for subfoveal choroidal neovascularization, either associated with the ocular histoplasmosis syndrome or idiopathic. I. Ophthalmic findings from a randomized clinical trial: Submacular Surgery Trials (SST) Group H Trial: SST Report No 9. Arch Ophthalmol 2004;122:1597-1611.
35. Verteporfin in Ocular Histoplasmosis (VOH) Study Group: Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin in the ocular histoplasmosis syndrome: one-year results of an uncontrolled, prospective case series. Ophthalmology 2002;109:1499-1505.
36. Verteporfin in Ocular Histoplasmosis Study Group: Photodynamic therapy with verteporfin in ocular histoplasmosis: uncontrolled, open-label two-year study. Ophthalmology 2004;111:1725-1733.
37. Adán A, Navarro M, Casaroli-Marano RP, et al: Intravitreal bevacizumab as initial treatment for choroidal neovascularization associated with presumed ocular histoplasmosis syndrome. Graefes Arch Clin Exp Ophthalmol 2007;245:1873-1875.
38. Schadlu R, Blinder KJ, Shah GK, et al: Intravitreal bevacizumab for choroidal neovascularization in ocular histoplasmosis. Am J Ophthalmol 2008;145:875-878.
39. Yoganathan P, Deramo VA, Lai JC, et al: Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration. Retina 2006;26:994-998.
40. Mirshahi A, Namavari S, Djalilian A, et al: Intravitreal bevacizumab (Avastin) for the treatment of cystoid macular edema in Beçhet's disease. Ocular Immunol Inflamm 2009;17:59-64.
41. Jampol LM, Sieving PA, Pugh D, et al: Multiple evanescent white dot syndrome. I. Clinical findings. Arch Ophthalmol 1984;102:671-674.
42. Gross NE, Yannuzzi LA, Freund KB, et al: Multiple evanescent white dot syndrome. Arch Ophthalmol 2006;124:493-500.
43. Sieving PA, Fishman GA, Jampol LM, Pugh D: Multiple evanescent white dot syndrome. II. Electrophysiology of the photoreceptors during retinal pigment epithelium disease. Arch Ophthalmol 1984;102:675-679.
44. Feigl B, Haas A, El-Shabrawi Y: Multifocal ERG in multiple evanescent white dot syndrome. Graefes Arch Clin Exp Ophthalmol 2002;240:615-621.
45. Li D, Kishi S: Restored photoreceptor outer segment damage in multiple evanescent white dot syndrome. Ophthalmology 2009:116: 762-770.
46. Wyhinny GJ, Jackson JL, Jampol JM: Subretinal neovascularization following multiple evanescent white dot syndrome. Arch Ophthalmol 1990;108:1384.
47. Rouvas AA, Ladas ID, Papakostas TD, et al: Intravitreal ranibizumab in a patient with choroidal neovascularization secondary to multiple evanescent white dot syndrome. Eur J Ophthalmol 2007;17:996-999.
48. Ryan SJ, Maumenee AE: Birdshot retinochoroidopathy. Am J Ophthalmol 1980;89:31-45.
49. Soubrane G, Bokobza R, Coscas G: Late developing lesions in birdshot retinochoroidopathy. Am J Ophthalmol 1990;109:204-210.
50. Brucker AJ, Deglin EA, Bene C, Hoffman ME: Subretinal choroidal neovascularization in birdshot retinochoroidopathy. Am J Ophthalmol 1985;99:40-44.
51. Fuerst DJ, Tessler HH, Fishman GA, et al: Birdshot retinochoroidopathy. Arch Ophthalmol 1984;102:214-219.
52. Nussenblatt RB, Mittal KK, Ryan SJ, et al: Birdshot retinochoroidopathy associated with HLA-A20 antigen and immune responsiveness to retinal S-antigen. Am J Ophthalmol 1982;94:147-158.
53. Nguyen QD, Shah SM, Hafiz G, et al: intravitreal bevacizumab causes regression of choroidal neovascularization secondary to diseases other than agerelated macular degeneration. Am J Ophthalmol 2008;145:257-266.
54. Cordero Coma M, Sobrin L, Onal S, et al: Intravitreal bevacizumab for treatment of uveitic macular edema. Ophthalmology 2007;114:p1574-1579.
55. Gass J D M: Acute posterior multifocal placoid pigment epitheliopathy. Arch Ophthalmol 1968;80:177-185.
56. Wolf MD, Alward WL, Folk JC: Long-term visual function in acute posterior multifocal placoid pigment epitheliopathy. Arch Ophthalmol 1991;109:800-803.
57. Isashiki M, Koide H, Yamashita T, Ohba N: Acute posterior multifocal placoid pigment epitheliopathy associated with diffuse retinal vasculitis and late haemorrhagic macular detachment. Br J Ophthalmol 1986;70:255-259.
58. Williams DF, Mieler WF: Long-term follow-up of acute multifocal posterior placoid pigment epitheliopathy. Br J Ophthalmol 1989;73:985-990.
59. Daniele S, Daniele C, Orcidi F, Tavano A: Progression of choroidal atrophy in acute posterior multifocal placoid pigment epitheliopathy. Ophthalmologica 1998;212:66-72.
60. Pagliarini S, Piguet B, Ffytche TJ, Bird AC: Foveal involvement and lack of visual recovery in APMPPE associated with uncommon features. Eye 1995;9:42-47.
61. Bowie EM, Sletten KR, Kayser DL, Folk JC: Acute posterior multifocal placoid pigment epitheliopathy and choroidal neovascularization. Retina 2005;25:362-364.
62. Espinasse-Berrod MA, Gotte D, Parent de Curzon H, Bayen MC, Campinchi R: A case of multiple epitheliopathy associated with subretinal neovascularizations. J Fr Ophtalmol 1988;11:191-194.
63. Mavrakanas N, Mendrinos E, Tabatabay C, Pournaras CJ: Intravitreal ranibizumab for choroidal neovascularization secondary to acute multifocal posterior placoid pigment epitheliopathy. Acta Ophthalmol 2010;88:e54-e55.
64. Schatz H, Maumenee AE, Patz A: Geographic helicoid peripapillary choroidopathy: clinical presentation and fluorescein angiographic findings. Trans Am Acad Ophthalmol Otolaryngol 1974;78:747-751.
65. Blumenkranz MS, Gass J D M, Clarkson JG: Atypical serpiginous choroiditis. Arch Ophthalmol 1982;100:1773-1778.
66. Laatikainen L, Erkkila H: Serpiginous choroiditis. Br J Ophthalmol 1974;58:777-783.
67. Mansour AM, Jampol LK, Packo HK, Hrisalamos NF: Macular serpiginous choroiditis. Retina 1988;8:125-129.
68. Chisholm IH, Gass J D M, Hutton WL: The late stages of serpiginous (geographic) choroiditis. Am J Ophthalmol 1976;82:343-348.
69. Masi RJ, O'Connor R, Kimura SJ: Anterior uveitis in geographic or serpiginous choroiditis. Am J Ophthalmol 1978;86:228-231.
70. Sahel JA, Weber M, Conlon MR, Albert DM: Pathology of the uveal tract; in Albert DM, Jakobiec FA (eds): Principles and Practices of Ophthalmology: Clinical Practice. Philadelphia. Saunders, 1994, vol 182, pp 2145-2179.
71. Wojno T, Meredith TA: Unusual findings in serpiginous choroiditis. Am J Ophthalmol 1982;94:650-653.
72. Laatikainen L, Erkkila H: Subretinal and disc neovascularization in serpiginous choroiditis. Br J Ophthalmol 1982;66:326-328.
73. Jampol JK, Orth D, Daily MJ, Rabb MF: Subretinal neovascularization with geographic (serpiginous) choroiditis. Am J Ophthalmol 1979;88:683-686.
74. Gass J D M: Serpiginous Choroiditis. Stereoscopic Atlas of Macular Diseases: Diagnosis and Treatment, ed 4. St Louis, Mosby, 1997, pp 158-165.
75. Christmas NH, Ok KT, Oh DM, Folk JC: Long-term follow-up of patients with serpiginous choroiditis. Retina 2002;22:550-556.
76. Song MH, Roh YJ: Intravitreal ranibizumab for choroidal neovascularisation in serpiginous choroiditis. Eye (Lond) 2009;23:1873-1875.
77. Golchet PR, Jampol LM, Wilson D, Yannuzzi LA, Ober M, Stroh E: Persistent placoid maculopathy. A new clinical entity. Trans Am Ophthalmol Soc 2006;104:108-120.
78. Golchet PR, Jampol LM, Wilson D, Yannuzzi LA, Ober M, Stroh E: Persistent placoid maculopathy. A new clinical entity. Ophthalmology 2007;114:1530-1540.
79. Parodi MB, Iacono P, Bandello F: Juxtafoveal choroidal neovascularization secondary to persistent placoid maculopathy treated with intravitreal bevacizumab. In press.
80. Rothova A, Suttorp-van Schulten MS, Frits Treffers W, Kijlstra A: Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol 1996;80:332-336.
81. Rosenbaum JT: Characterization of uveitis associated with spondyloarthritis. J Rheumatol 1989;16:792-796.
82. + iridocyclitis: incidence; value of surgical treatment. J Fr Ophtalmol 1988;11:561-566.
83. Markomichelakis NN, Halkiadakis I, Pantelia E, et al: Patterns of macular edema in patients with uveitis: qualitative and quantitative assessment using optical coherence tomography. Ophthalmology 2004;111:946-953.
84. Guex-Crosier Y: The pathogenesis and clinical presentation of macular edema in inflammatory diseases. Doc Ophthalmol 1999;97:297-309.
85. Papadaki T, Zacharopoulos I, Iaccheri B, et al: Somatostatin for uveitic cystoid macular edema. Ocul Immunol Inflamm 2005;13:469-470.